Special Issue | 29 March 2013Cancer Genomics
INTRODUCTION—With the completion of the human genome in 2001, many researchers immediately set their sights on using this information
to better understand the genetics and, more recently, epigenetic effects identified during the initiation, development, and
progression of cancer. Moving from the pre-genome era identification of single gene variants associated with hereditary cancers,
advances in sequencing technology have enabled the use of a whole-genome approach to examine the differences between the genomes
of, and epigenetic regulation of, tumor and patient DNA. This issue of Science examines how these advances are shaping our current understanding of cancer at the genomic level. [Read the full introduction]
All of the articles in this special section are FREE with registration. Sign up today!
From Science
News Focus
Elizabeth Pennisi
With her passion for DNA sequencing technology, Elaine Mardis now hopes to help cancer patients.
News Focus
Jocelyn Kaiser
Increasing genetic evidence that tumors contain a heterogeneous mix of cells may explain why cancer treatments often fail.
Review Free Access
B. Vogelstein et al.
Cancer genome analyses have underscored the complexity of the disease and suggested new guiding principles for patient care.
Review
O. Kilpivaara and L. A. Aaltonen
Standards are needed to optimally utilize data obtained from sequencing cancer patients genomes.
Review
H. L. McLeod
Genetic variants of both the patient and tumor need to be taken into account in determining optimal cancer drug therapies.
Review
M. L. Suvà et al.
Oncogenic transformation, tumor heterogeneity, and cancer stem cell models show parallel molecular mechanisms.
Editorial
E. T. Liu
The complexity of cancer biology requires a systems dynamics view of the disease.
From Science Signaling
Science Signaling Editorial Guide
N. R. Gough
Understanding alterations in signaling networks is key to developing rational, personalized cancer therapies.
Science Signaling Perspective
W. G. Cance et al.
Targeting the scaffold of focal adhesion kinase is a therapeutic opportunity to inhibit signaling pathways selectively in
cancer cells.
Science Signaling Perspective
M. R. Webster and A. T. Weeraratna
The repertoire of Wnt receptors and coreceptors in melanoma cells may determine whether β-catenin promotes metastasis.
Science Signaling Perspective
A. Roulston et al.
Drugs that target oncogenic receptor tyrosine kinases activate parallel signaling pathways that trigger cell death.
Science Signaling Research Article
G. R. Bean et al.
Combining drugs that inhibit anti-apoptotic proteins with oncogenic kinase inhibitors may overcome drug resistance in cancer
therapy.
Science Signaling Research Article
C. Hartzell et al.
Understanding the signaling mechanisms that can lead to T cell leukemia may enable personalized therapies.
Science Signaling Research Resource
P. Casado et al.
Computational analysis of phosphoproteomics data predicts the sensitivity of leukemia cells to kinase inhibitors.
Science Signaling Perspective
M. B. Yaffe
Signaling networks may provide greater return in the investment in cancer research.
Science Signaling Protocol
30 January 2015
23 January 2015
19 December 2014
21 November 2014
31 October 2014
10 October 2014
